Literature DB >> 20380511

Focal therapy and imaging in prostate and kidney cancer: high-intensity focused ultrasound ablation of small renal tumors.

Markus Margreiter1, Michael Marberger.   

Abstract

The rising incidence of small, incidentally detected renal masses in elderly, infirm patients has raised interest in minimally invasive, energy ablative techniques. High-intensity focused ultrasound (HIFU) delivers ultrasonic energy, resulting in heat and tissue destruction in the targeted tissue at a selected depth. In contrast to radiofrequency ablation and cryoablation, HIFU does not require puncturing the tumor, avoiding the high risk of hemorrhage or tumor spillage. While the extracorporeal approach shows unsatisfactory results, laparoscopic HIFU appears to be a promising alternative treatment option. Problems with respiratory movement and interphases, as seen in extracorporeal HIFU, are avoided when the transducer is brought directly to the target by laparoscopic HIFU. Potential benefits of laparoscopic HIFU are decreased morbidity, shorter hospitalization and convalescence, and preservation of renal function. Nevertheless, further prospective studies have to be performed to define the oncological success of HIFU as an alternative to open and laparoscopic surgery in small renal masses.

Entities:  

Mesh:

Year:  2010        PMID: 20380511     DOI: 10.1089/end.2009.0624

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  4 in total

1.  SonoKnife: feasibility of a line-focused ultrasound device for thermal ablation therapy.

Authors:  Duo Chen; Rongmin Xia; Xin Chen; Gal Shafirstein; Peter M Corry; Robert J Griffin; Jose A Penagaricano; Ozlem E Tulunay-Ugur; Eduardo G Moros
Journal:  Med Phys       Date:  2011-07       Impact factor: 4.071

2.  The ongoing history of thermal therapy for cancer.

Authors:  Evan S Glazer; Steven A Curley
Journal:  Surg Oncol Clin N Am       Date:  2010-12-13       Impact factor: 3.495

3.  In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.

Authors:  Eric J Sorscher; Jeong S Hong; Paula W Allan; William R Waud; William B Parker
Journal:  Cancer Chemother Pharmacol       Date:  2012-07-04       Impact factor: 3.333

Review 4.  Management of small renal masses--update 2011.

Authors:  C Surcel; C Mirvald; C Gingu; R Stoica; I Sinescu
Journal:  J Med Life       Date:  2011-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.